title: The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse.
abstract: Stress and renewed contact with drug (a "slip") have been linked to persisting relapse of methamphetamine abuse. Human brain microglial activation has been linked with methamphetamine abuse, and inhibitors of glial cell activation, certain phosphodiesterase (PDE) inhibitors, and glial cell derived neurotrophic factor (GDNF) have been reported to modulate drug abuse effects. Our objective was to determine whether the glial cell attenuator, 3-isobutyryl-2-isopropylpyrazolo-[1,5-a]pyridine (AV411, ibudilast), a non-selective PDE inhibitor and promoter of GDNF, could reduce stress- and methamphetamine prime-induced reinstatement of methamphetamine-seeking behavior. Male Long-Evans hooded rats were trained to lever press reinforced with 0.1 mg/kg i.v. methamphetamine infusion according to fixed-ratio 1 (FR1) reinforcement schedules during daily, 2-hour experimental sessions. After performance had stabilized, lever pressing was extinguished for 12 consecutive sessions and doses of 0 (vehicle), 2.5 and 7.5 mg/kg AV411 were then administered intraperitoneally b.i.d. on the last 2 days of extinction and then once on the testday to separate groups of 12 rats. During testing, the rats were given 15 min of intermittent footshock or a 1 mg/kg i.p. methamphetamine prime followed by a 2-hour reinstatement test session. AV411 significantly reduced response levels of footshock-induced (2.5 and 7.5 mg/kg) and prime-induced (7.5 mg/kg) reinstatement of extinguished methamphetamine-maintained responding. AV411 has properties consistent with the ability to attenuate relapse precipitated by stress and methamphetamine "slips" during abstinence. These results thus reinforce interest in atypical neurobiological mechanisms which could be exploited for developing novel medications for treating drug abuse disorders.
authors.affiliation: Department of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 3298-0613, USA. pbeardsl@vcu.edu
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Beardsley
authors.forename: Keith L
authors.initials: KL
authors.lastname: Shelton
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hendrick
authors.forename: Kirk W
authors.initials: KW
authors.lastname: Johnson
mesh_terms: D019969:Amphetamine-Related Disorders / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D007274:Injections, Intraperitoneal; D008297:Male; D008694:Methamphetamine / Q000378:metabolism*; D009457:Neuroglia / Q000187:drug effects* / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D020318:Rats, Long-Evans; D055502:Secondary Prevention; D013315:Stress, Psychological / Q000503:physiopathology*; D013997:Time Factors; D007212:Indolizines; D011720:Pyrazoles
chemical_list: D008694:Methamphetamine; D010726:Phosphodiesterase Inhibitors; D011725:Pyridines; C038366:ibudilast; D007212:Indolizines; D011720:Pyrazoles
references.citation: Expert Opin Investig Drugs. 2007 Jul;16(7):935-50
references.pmid: 17594181
references.citation: Neuron. 2000 Apr;26(1):247-57
references.pmid: 10798408
references.citation: Psychopharmacology (Berl). 2008 Feb;196(2):233-41
references.pmid: 17909751
references.citation: Eur J Pharmacol. 2006 May 24;538(1-3):39-42
references.pmid: 16674936
references.citation: Behav Brain Res. 2001 Jan 8;118(1):85-93
references.pmid: 11163637
references.citation: FASEB J. 2007 Jul;21(9):1994-2004
references.pmid: 17356005
references.citation: Synapse. 2000 Mar 15;35(4):243-9
references.pmid: 10657033
references.citation: Glia. 2003 Sep;43(3):218-03
references.pmid: 12898701
references.citation: Nature. 1994 Jun 30;369(6483):744-7
references.pmid: 7911978
references.citation: Proc Natl Acad Sci U S A. 2006 May 30;103(22):8523-7
references.pmid: 16717181
references.citation: J Pharmacol Exp Ther. 2004 Oct;311(1):1-7
references.pmid: 15163680
references.citation: Trends Neurosci. 2005 Dec;28(12):661-9
references.pmid: 16246435
references.citation: Brain Res. 1998 Dec 14;814(1-2):120-6
references.pmid: 9838075
references.citation: Biol Psychiatry. 2007 Apr 1;61(7):890-901
references.pmid: 17046726
references.citation: Brain Behav Immun. 2009 Feb;23(2):240-50
references.pmid: 18938237
references.citation: J Neurosci Res. 2004 Oct 15;78(2):250-8
references.pmid: 15378610
references.citation: Neuropsychopharmacology. 2004 Jul;29(7):1270-81
references.pmid: 15039771
references.citation: Nat Neurosci. 1998 Dec;1(8):683-92
references.pmid: 10196584
references.citation: Eur J Neurosci. 2004 May;19(9):2561-8
references.pmid: 15128409
references.citation: Jpn J Pharmacol. 2000 Jun;83(2):113-8
references.pmid: 10928323
references.citation: J Neurosci. 1996 Dec 15;16(24):8132-9
references.pmid: 8987838
references.citation: Psychopharmacology (Berl). 2007 Feb;190(2):171-80
references.pmid: 17119930
references.citation: Ann N Y Acad Sci. 2004 Oct;1025:504-7
references.pmid: 15542755
references.citation: Glia. 2001 Oct;36(1):11-21
references.pmid: 11571780
references.citation: Pharmacol Biochem Behav. 2008 Sep;90(3):434-40
references.pmid: 18456312
references.citation: Behav Brain Res. 2006 Oct 2;173(1):39-46
references.pmid: 16857277
references.citation: Br J Clin Pharmacol. 2008 Dec;66(6):792-801
references.pmid: 19032723
references.citation: Neuron Glia Biol. 2006 Nov;2(4):279-91
references.pmid: 18176632
references.citation: Brain Res. 1999 Aug 7;837(1-2):203-12
references.pmid: 10434004
references.citation: Neuroscience. 2003;122(2):499-513
references.pmid: 14614914
references.citation: Eur J Pharmacol. 2002 Jul 19;448(2-3):165-8
references.pmid: 12144937
references.citation: Neuropharmacology. 2004 Mar;46(3):404-11
references.pmid: 14975696
references.citation: Ann N Y Acad Sci. 2000 Sep;914:127-36
references.pmid: 11085315
references.citation: Eur J Pharmacol. 2007 Jun 22;565(1-3):113-8
references.pmid: 17408614
references.citation: Br J Pharmacol. 2001 Mar;132(5):1111-7
references.pmid: 11226142
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2003 May;367(5):490-9
references.pmid: 12684743
references.citation: Eur J Pharmacol. 2007 Nov 21;574(1):39-48
references.pmid: 17869241
references.citation: Brain Res. 1999 May 8;827(1-2):104-12
references.pmid: 10320698
references.citation: ScientificWorldJournal. 2007 Nov 02;7:98-111
references.pmid: 17982582
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1381-93
references.pmid: 16839653
references.citation: Neurosci Lett. 2004 Sep 9;367(3):349-54
references.pmid: 15337264
references.citation: Expert Opin Pharmacother. 2009 Dec;10(17):2897-904
references.pmid: 19929708
references.citation: Neuropsychopharmacology. 1995 Aug;13(1):33-9
references.pmid: 8526969
references.citation: Neuroscience. 2004;124(2):377-86
references.pmid: 14980387
references.citation: Eur J Pharmacol. 1996 Sep 26;312(2):163-70
references.pmid: 8894591
references.citation: Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1964-9
references.pmid: 11172059
references.citation: Brain Behav Immun. 2007 Feb;21(2):131-46
references.pmid: 17175134
references.citation: Neuropharmacology. 2004 Apr;46(5):734-42
references.pmid: 14996551
references.citation: Biol Psychiatry. 2004 Jun 1;55(11):1082-9
references.pmid: 15158427
references.citation: Arch Med Res. 2006 Jan;37(1):11-8
references.pmid: 16314180
references.citation: Exp Neurol. 2004 May;187(1):47-57
references.pmid: 15081587
references.citation: J Neurosci. 2007 Aug 15;27(33):8816-25
references.pmid: 17699663
references.citation: Neurosci Res. 2001 Mar;39(3):281-6
references.pmid: 11248367
references.citation: Nature. 1998 Jan 15;391(6664):281-5
references.pmid: 9440691
references.citation: Neuropsychopharmacology. 2006 Nov;31(11):2476-88
references.pmid: 16407899
references.citation: Behav Brain Res. 2007 Apr 16;179(1):167-71
references.pmid: 17331595
references.citation: Ann N Y Acad Sci. 2006 Aug;1074:272-81
references.pmid: 17105923
references.citation: Biol Psychiatry. 2007 Sep 15;62(6):658-68
references.pmid: 17217924
references.citation: Glia. 2004 Aug 15;47(3):209-16
references.pmid: 15252809
references.citation: Neuropsychopharmacology. 2004 Aug;29(8):1470-8
references.pmid: 15085091
references.citation: Neuropharmacology. 2009 Apr;56(5):856-65
references.pmid: 19371575